Edwards Lifesciences Acquires BMEYE

New Post Public Reply Private Reply Replies (0) Message Board

Oct 15, 2012 at 6:43 AM

Edwards Lifesciences Acquires BMEYE

Critical Care Portfolio Expands to Include Non-Invasive Platform

IRVINE, CA, October 10, 2012 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the acquisition of BMEYE B.V., a privately held Dutch company that specializes in the development of non-invasive technology for advanced hemodynamic monitoring. BMEYE's technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.

"BMEYE's unique non-invasive technology platform complements our existing portfolio and will provide clinicians with critical, comprehensive hemodynamic monitoring information for a broader range of patients. Numerous studies have concluded that therapy guided by hemodynamic monitoring improves patient outcomes and reduces complications and lengths of hospital stays," said Carlyn Solomon, Edwards' corporate vice president, critical care and vascular. "This acquisition supports our ongoing commitment to build and strengthen our offerings for clinicians and patients, and reinforces our leadership in hemodynamic monitoring."

BMEYE's monitoring products work with a non-invasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other important hemodynamic parameters. Currently, BMEYE's products are approved for sale in the United States, throughout Europe and in several other countries.

Rob de Ree, chief executive officer of BMEYE said, "BMEYE has a solid history of developing innovative hemodynamic monitoring solutions. We look forward to joining the Edwards team to extend the reach of our existing products, and to continue to develop novel technologies to help clinicians and improve patient care worldwide."

While BMEYE's products have primarily been used by clinicians outside of the hospital, over the next 18 months, Edwards plans to further develop BMEYE's technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.

The purchase price was EUR 32.5 million (approximately $42 million). Edwards expects the net earnings impact from this transaction to be immaterial in 2012, and slightly dilutive in 2013. Additional details will be forthcoming when the company provides 2013 financial guidance in December.

About Hemodynamic Monitoring
Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to the tissues. Healthcare providers use this information to detect changes or problems in a patient's status that will allow for informed, immediate treatment decisions. Edwards has been developing products and educational resources to help clinicians manage critically ill patients for more than 40 years. Its current product portfolio includes invasive and minimally invasive technologies designed specifically for patients who are critically ill or undergoing surgical procedures. With the addition of a non-invasive platform, Edwards can uniquely offer clinicians the broadest range of monitoring products, allowing them to select the most appropriate technology for each patient, and apply this important monitoring to a larger patient population.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com .

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited statements of Messrs. Solomon and de Ree, expected benefits of the BMEYE technology, plans for product development and expectations for net earnings impact. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the Company will make additional updates or corrections.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include unexpected results of expanded clinical experience; uncertainties associated with the Company's success in developing new products and expanding its markets, creating new market opportunities for its products and avoiding manufacturing and quality issues; unexpected delays in regulatory approvals; the availability and quality of competitive products; and other risks detailed in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2011, which are available at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo and EV1000 are trademarks of Edwards Lifesciences Corporation.

# # #

Contact Information:

Media Contact: Adrienne Turner or Sarah Huoh 949-250-5070
Investor Contact: David K. Erickson 949-250-6826

Edwards Lifesciences Corp. (EW) Stock Research Links

EW Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Boosting Mental Health Care for Veterans in Tampa

Transforming Access to Mental Health Care When it comes to mental health, Tampa General is raising the stakes for veterans. They're not just sticking to conventional paths but blazing new trails with a coordinated set of initiatives for the military community. From building resilience to preventing suicide, they're throwing down one hell of an effort. A Federally Backed...

Flyers Fundraiser Supports Mental Health Advocacy in NJ and PA

Blockbusters on Ice, Support Beyond the Rink Here's a twist for hockey fans out there: snagging tickets to catch the Philadelphia Flyers might pack more punch off the ice than on it. Why? Because, for every ticket you grab through Digital Elements Group's special link, $5 is pumped straight into the veins of mental health advocacy in New Jersey and Pennsylvania. Pretty...

InMotion's 2026 Black Friday: Massive Hosting Discounts

InMotion Hosting's Black Friday Bonanza You know the deal; when Black Friday rolls around, folks expect a blitz of sales, like a stampede through the digital aisles. This year, InMotion Hosting isn't just whispering in the wind—they're shouting with a hefty price slash across their offerings. I'm talking about up to 75% off on hosting and a 50% discount on managed...

TNL Mediagene: Strategic Moves Shake Up Asian Market

Shake-Ups in the Asian Tech Space Something's stirring in the Asian tech jungle, and it's TNL Mediagene making waves. With a dramatic one-two punch, they're managing a business sell-off and bringing in fresh equity. What does all this mean for the market and investors? Let's dig in. Japanese Business: A Clean Break TNL Mediagene just parted ways with its Japanese...

Ares Management Faces Fintech with $691B Assets

Anticipation Builds: Ares Awaits TD Cowen Spotlight Ah, Ares Management, the Wall Street heavyweight clocking a colossal $691 billion in assets. Now, they’re angling to dish out some strategic insights. With the TD Cowen 2026 Financials & Fintech Conference set to roll on November 18, what’s better than watching these investment titans take the stage with their CFO...

Goranson Bain Ausley Welcomes Marichalar: Family Law Focus

Strengthening San Antonio's Family Law Field Brenda Marichalar is joining the ranks at Goranson Bain Ausley (GBA) with a reputation built on solid courtroom chops and a knack for making clients feel like they’re more than just case numbers. She’s landing right in San Antonio, a region that’s not just about the riverwalks and missions, but about real families...

Q32 Bio's Ambitious Steps into Global Conferences

Q32 Bio Takes the Stage at Jefferies Who would've thought? Q32 Bio, strutting their stuff at the 2026 Jefferies Global Healthcare Conference in London. Mark your calendars, folks, for November 18, 2026, because that's when they're jumping into the spotlight with a fireside chat. This event isn't just another tiny ripple; it's a chance for Q32 to showcase their innovative...

EF English Live: Boosting Careers with Language Skills

Riding the English Proficiency Wave for Career Growth Everyone knows that being able to speak English is more than just a golden ticket to deeper Netflix rabbit holes; it's a damn necessity if you're dealing with global markets. You get those international clients on the line, and suddenly, your high school French isn't doing much for you. Take EF English Live, a platform...

OptiMantra's AI Scribe: Transforming Clinic Workflows

Cutting Through the Noise: AI Scribe's Pragmatic Impact OptiMantra's fresh launch of AI Scribe isn't just another gadget on the shelf—it's gunning for the throat of that time-sucking monster called after-hours charting. You'd think clinic management would be about patients first, right? But turns out, the devil's in the details, with docs burning midnight oil drafting...